Table 3.

Summary of the early randomized controlled trials on FMT in mild to moderate UC

Study	Rossen et al.	Moayyedi	Paramsothy	Costello	Haifer
Route	Nasoduodenal	Enema	Colon (× 1) + enema (40)	Colon (1) + enema (× 2)	2 weeks Abx (Amox/metro/doxy) + oral lyophilized capsule
Endpoint	Week 12	Week 7	Week 8	Week 8	Week 8
Disease severity	SCCAI 4–11, endoscopic subscore ≥ 1	Mayo ≥ 4, endoscopic subscore ≥ 1	Mayo 4–10	Mayo 3–10, endoscopic subscore ≥ 2	Mayo 4–10, endoscopic subscore ≥ 1
Primary outcome remission definition	SCCAI ≤ 2, endoscopic Mayo improved by ≥ 1	Total Mayo ≤ 2, endoscopic Mayo = 0	Total Mayo ≤ 2, endoscopic Mayo improved by ≥ 1 point	Total Mayo ≤ 2, endoscopic Mayo ≤ 1	Total Mayo ≤ 2, endoscopic Mayo improved by ≤ 1 point, steroid-free clinical remission
Control	Autologous	Water	Saline	Autologous	Placebo
Volume	120 ml	50 ml	150 ml	200 ml + 100 ml	Capsule 0.35 g lyophilized stool @
Timing	Weeks 0 and 3	1/week	5/weeks	3 times	Daily
Duration	3 weeks	6 weeks	8 weeks	1 week	8 weeks
Number of FMTs	2	6	41	3	24 capsules daily 1st week, 12 capsules daily 2nd week, 6 capsules daily 3rd to 8th weeks
References	[26]	[25]	[64]	[14]	[65]